Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
A new clinical study led by the National Eye Institute (NEI), part of the National Institutes of Health, will follow 500 people over five years to learn more about the natural history of early age-related macular degeneration (AMD).
A competition for radical ideas in the fight against blindness will move to its next phase by challenging participants to build functioning human retina prototypes.
The recent approval of two novel medications for glaucoma – the first new medications for the disorder in nearly 18 years – are fruit borne from decades of foundational scientific research supported by the National Eye Institute (NEI).
Common, unavoidable eye movements may be a cause of glaucoma in people with normal intraocular pressure (normal-tension glaucoma), according to new research supported by the National Eye Institute.
Scientists at the National Eye Institute (NEI) report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE) are essential for the survival of the retina’s light-sensing photoreceptors.
In a major step forward in the battle against macular degeneration, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight.
Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of the cornea.